Immunotherapy Efficacy Up With Gal-1/SIT Co-Administration

This article originally appeared here.
Share this content:
Immunotherapy Efficacy Up With Gal-1/SIT Co-Administration
Immunotherapy Efficacy Up With Gal-1/SIT Co-Administration

MONDAY, July 24, 2017 (HealthDay News) -- Galectin-1 (Gal-1), allergen-specific immunotherapy (SIT) co-administration may suppress allergic responses in the intestine more than use of SIT or Gal-1 alone, according to an experimental study published online July 18 in Allergy.

Li-Tao Yang, Ph.D., from the Shenzhen University School of Medicine in China, and colleagues developed an intestinal allergy mouse model to examine whether Gal-1 administration promotes and prolongs the efficacy of SIT. In sensitized mice, the authors assessed the impact of co-administration of SIT and Gal-1 on suppression of allergic responses, prevention of mast cell activation, and generation of antigen-specific regulatory T cells (Tregs).

The researchers found that, compared with use of SIT or Gal-1 alone, co-administration markedly suppressed the allergic responses in the mouse intestine. Gal-1 bound to immunoglobulin E/FcεRI complexes on the mast cell surface to prevent mast cell activation during SIT. The SIT-generated allergen-specific Tregs were promoted by Gal-1 in the intestine of the sensitized mice. The efficacy of immunotherapy for suppressing allergic responses in the intestine was enhanced significantly by co-administration of Gal-1 and SIT, which lasted for at least 12 months.

"Long term effects of specific immunotherapy on intestinal allergy can be achieved with Gal-1/SIT therapy by inhibiting mast cell activation and facilitating Treg development," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

For Hepatitis B Patients, Aspirin Tied to Lower Risk of HCC

For Hepatitis B Patients, Aspirin Tied to Lower ...

5 years of aspirin therapy linked to significantly lower incidence of hepatocellular carcinoma

High Percentage of HIV-Diagnosed Women Not in Care

High Percentage of HIV-Diagnosed Women Not in Care

62 percent of women with positive test had previously received the diagnosis but no care

CDC Updates Zika Guidance for Infant Care

CDC Updates Zika Guidance for Infant Care

Recommendations include evaluation and management of infants with possible infection

is free, fast, and customized just for you!

Already a member?

Sign In Now »